Risk Factors for Serious Prescription Opioid-Related Toxicity or Overdose among Veterans Health Administration Patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      Objective Prescription opioid use and deaths related to serious toxicity, including overdose, have increased dramatically in the United States since 1999. However, factors associated with serious opioid-related respiratory or central nervous system ( CNS) depression or overdose in medical users are not well characterized. The objective of this study was to examine the factors associated with serious toxicity in medical users of prescription opioids. Design Retrospective, nested, case-control analysis of Veterans Health Administration ( VHA) medical, pharmacy, and health care resource utilization administrative data. Subjects Patients dispensed an opioid by VHA between October 1, 2010 and September 30, 2012 (N = 8,987). Methods Cases (N = 817) experienced life-threatening opioid-related respiratory/ CNS depression or overdose. Ten controls were randomly assigned to each case (N = 8,170). Logistic regression was used to examine associations with the outcome. Results The strongest associations were maximum prescribed daily morphine equivalent dose ( MED) ≥ 100 mg (odds ratio [ OR] = 4.1, 95% confidence interval [ CI], 2.6-6.5), history of opioid dependence ( OR = 3.9, 95% CI, 2.6-5.8), and hospitalization during the 6 months before the serious toxicity or overdose event ( OR = 2.9, 95% CI, 2.3-3.6). Liver disease, extended-release or long-acting opioids, and daily MED of 20 mg or more were also significantly associated. Conclusions Substantial risk for serious opioid-related toxicity and overdose exists at even relatively low maximum prescribed daily MED, especially in patients already vulnerable due to underlying demographic factors, comorbid conditions, and concomitant use of CNS depressant medications or substances. Screening patients for risk, providing education, and coprescribing naloxone for those at elevated risk may be effective at reducing serious opioid-related respiratory/ CNS depression and overdose in medical users of prescription opioids. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Pain Medicine is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)